Cash on Hand for Gilead Sciences (GILD)
According to Gilead Sciences's latest reported financial statements, the company's latest reported cash and short-term investments is $10.61B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
GILD
Currently viewingCash on HandSwitch metric
Latest period
$10.61B
YoY change
-8.3%
5Y CAGR
+7.4%
Peak year (2018)
$30.09B
Latest annual
$10.61B
Cash on Hand history chart for Gilead Sciences (GILD) from 1990 to 2025
Cash on Hand history table for Gilead Sciences (GILD) from 1990 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $10.61B | -8.3% | ||
| 2024 | $11.57B | +59.3% | ||
| 2023 | $7.26B | +13.8% | ||
| 2022 | $6.38B | -2.1% | ||
| 2021 | $6.52B | -12.0% | ||
| 2020 | $7.41B | -69.6% | ||
| 2019 | $24.35B | -19.1% | ||
| 2018 | $30.09B | +17.9% | ||
| 2017 | $25.51B | +114.5% | ||
| 2016 | $11.89B | -18.6% | ||
| 2015 | $14.61B | +44.2% | ||
| 2014 | $10.13B | +375.0% | ||
| 2013 | $2.13B | +14.5% | ||
| 2012 | $1.86B | -81.2% | ||
| 2011 | $9.90B | +371.7% | ||
| 2010 | $2.10B | +26.7% | ||
| 2009 | $1.66B | -7.4% | ||
| 2008 | $1.79B | +52.7% | ||
| 2007 | $1.17B | +25.1% | ||
| 2006 | $936.85M | -59.5% | ||
| 2005 | $2.31B | +84.3% | ||
| 2004 | $1.25B | +77.4% | ||
| 2003 | $707.00M | -25.0% | ||
| 2002 | $942.37M | +61.7% | ||
| 2001 | $582.85M | +13.6% | ||
| 2000 | $512.88M | +74.2% | ||
| 1999 | $294.39M | +191.2% | ||
| 1998 | $101.10M | +215.9% | ||
| 1997 | $32.00M | -75.8% | ||
| 1996 | $132.00M | +381.8% | ||
| 1995 | $27.40M | -9.9% | ||
| 1994 | $30.40M | — | ||
| 1992 | $2.10M | -97.6% | ||
| 1991 | $87.90M | +753.4% | ||
| 1990 | $10.30M | — |
Cash on Hand values are taken from Gilead Sciences's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Gilead Sciences (GILD) cash and short-term investments totalled $10.61B – declined 8.3% year-over-year.
Gilead Sciences cash and short-term investments has recorded the values shown across consecutive periods, with a +7.4% compound annual growth rate over 2020–2025 (5 years).
Gilead Sciences cash and short-term investments peaked at $30.09B in 2018; the latest annual figure is $10.61B in 2025 (64.8% below peak).
$30.09B stands as the all-time-high annual cash and short-term investments, posted in 2018, against a low of $2.10M during 1992.
Gilead Sciences (GILD) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $11.85B.
Gilead Sciences Cash on Hand by Year
Gilead Sciences Cash on Hand 2025: $10.61B
Gilead Sciences cash and short-term investments in 2025 was $10.61B, declined 8.3% below 2024.
Gilead Sciences Cash on Hand 2024: $11.57B
Gilead Sciences cash and short-term investments in 2024 was $11.57B, surged 59.3% from 2023.
Gilead Sciences Cash on Hand 2023: $7.26B
Gilead Sciences cash and short-term investments in 2023 was $7.26B, grew 13.8% from 2022.
Gilead Sciences Cash on Hand 2022: $6.38B
Gilead Sciences cash and short-term investments in 2022 was $6.38B, edged down 2.1% below 2021.
Gilead Sciences Cash on Hand 2021: $6.52B
Gilead Sciences cash and short-term investments in 2021 was $6.52B.
See more financial history for Gilead Sciences (GILD).
Sector peers — Cash on Hand
Companies in the same sector as Gilead Sciences, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Gilead Sciences's cash and short-term investments?
- Latest reported cash and short-term investments for Gilead Sciences (GILD) is $10.61B (period ending December 31, 2025).
How has Gilead Sciences cash and short-term investments changed year-over-year?
- Gilead Sciences (GILD) cash and short-term investments changed -8.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Gilead Sciences cash and short-term investments?
- Gilead Sciences (GILD) cash and short-term investments compound annual growth rate is +7.4% over the most recent 5 years available.
When did Gilead Sciences cash and short-term investments hit its highest annual value?
- Gilead Sciences cash and short-term investments reached its highest annual value of $30.09B in 2018.
What was Gilead Sciences cash and short-term investments in 2024?
- Gilead Sciences (GILD) cash and short-term investments in 2024 was $11.57B.
What was Gilead Sciences cash and short-term investments in 2025?
- Gilead Sciences (GILD) cash and short-term investments in 2025 was $10.61B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
GILD Overview
Company profile, financial tools, and key metrics
GILD Revenue Counter
Earns $933.60 every second. See per minute, hour, and day.
GILD Earnings Counter
Earns $269.85 per second net profit. See per minute, hour, and day.
GILD Economic Scale
Exceeds Albania's GDP. Compare with world economies.
GILD What If Invested
What if you had invested $1,000? See historical returns from any date.
GILD How It Makes Money
Discover visual breakdown of $29.44B in revenue — where it comes from and where it goes.
GILD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
GILD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
GILD Daily Price Character
Explosive · 48.7% historical win rate (green days). Streaks & record days.
GILD Buybacks
1.26% TTM buyback yield. Shareholder yield & SBC comparison.
GILD Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
GILD Dividend Profile
Yield: 2.48%. Safety: 8/8. See full history.
GILD Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
GILD Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.